| HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects M J Buzón, M Massanella, JM Llibre, A Esteve, V Dahl, MC Puertas, ... Nature medicine 16 (4), 460-465, 2010 | 660 | 2010 |
| Capture and transfer of HIV-1 particles by mature dendritic cells converges with the exosome-dissemination pathway N Izquierdo-Useros, M Naranjo-Gómez, J Archer, SC Hatch, I Erkizia, ... Blood, The Journal of the American Society of Hematology 113 (12), 2732-2741, 2009 | 301 | 2009 |
| Siglec-1 Is a Novel Dendritic Cell Receptor That Mediates HIV-1 Trans-Infection Through Recognition of Viral Membrane Gangliosides N Izquierdo-Useros, M Lorizate, MC Puertas, MT Rodriguez-Plata, ... PLoS biology 10 (12), e1001448, 2012 | 265 | 2012 |
| HIV and mature dendritic cells: Trojan exosomes riding the Trojan horse? N Izquierdo-Useros, M Naranjo-Gómez, I Erkizia, MC Puertas, FE Borràs, ... PLoS pathogens 6 (3), e1000740, 2010 | 238 | 2010 |
| Definition of the viral targets of protective HIV-1-specific T cell responses B Mothe, A Llano, J Ibarrondo, M Daniels, C Miranda, J Zamarreño, ... Journal of translational medicine 9, 1-20, 2011 | 191 | 2011 |
| Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study JM Llibre, MJ Buzón, M Massanella, A Esteve, V Dahl, MC Puertas, ... Antiviral therapy 17 (2), 355-364, 2012 | 144 | 2012 |
| Establishment and replenishment of the viral reservoir in perinatally HIV-1-infected children initiating very early antiretroviral therapy M Martínez-Bonet, MC Puertas, C Fortuny, D Ouchi, MJ Mellado, P Rojo, ... Clinical Infectious Diseases 61 (7), 1169-1178, 2015 | 135 | 2015 |
| HIVconsv vaccines and romidepsin in early-treated HIV-1-infected individuals: safety, immunogenicity and effect on the viral reservoir (Study BCN02) B Mothe, M Rosás-Umbert, P Coll, C Manzardo, MC Puertas, ... Frontiers in immunology 11, 823, 2020 | 84 | 2020 |
| Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection MC Puertas, M Massanella, JM Llibre, M Ballestero, MJ Buzon, D Ouchi, ... Aids 28 (3), 325-334, 2014 | 83 | 2014 |
| Exosomes and retroviruses: the chicken or the egg? N Izquierdo‐Useros, MC Puertas, FE Borràs, J Blanco, J Martinez‐Picado Cellular microbiology 13 (1), 10-17, 2011 | 82 | 2011 |
| Natural killer cells are required for accelerated type 1 diabetes driven by interferon-β A Alba, R Planas, X Clemente, J Carrillo, R Ampudia, MC Puertas, ... Clinical & Experimental Immunology 151 (3), 467-475, 2008 | 76 | 2008 |
| IFNβ accelerates autoimmune type 1 diabetes in nonobese diabetic mice and breaks the tolerance to β cells in nondiabetes-prone mice A Alba, MC Puertas, J Carrillo, R Planas, R Ampudia, X Pastor, F Bosch, ... The Journal of Immunology 173 (11), 6667-6675, 2004 | 76 | 2004 |
| CCR5 Δ32 homozygous cord blood allogeneic transplantation in a patient with HIV: a case report RF Duarte, M Salgado, I Sánchez-Ortega, M Arnan, C Canals, ... The Lancet HIV 2 (6), e236-e242, 2015 | 75 | 2015 |
| Deep molecular characterization of HIV-1 dynamics under suppressive HAART MJ Buzon, FM Codoner, SDW Frost, C Pou, MC Puertas, M Massanella, ... PLoS pathogens 7 (10), e1002314, 2011 | 75 | 2011 |
| Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1 B Mothe, N Climent, M Plana, M Rosàs, JL Jiménez, ... Journal of Antimicrobial Chemotherapy 70 (6), 1833-1842, 2015 | 73 | 2015 |
| Sensitive quantification of the HIV-1 reservoir in gut-associated lymphoid tissue S Morón-López, MC Puertas, C Gálvez, J Navarro, A Carrasco, M Esteve, ... PloS one 12 (4), e0175899, 2017 | 70 | 2017 |
| Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1: a phase 1b/2a, randomized trial JD Gunst, MH Pahus, M Rosás-Umbert, IN Lu, T Benfield, H Nielsen, ... Nature medicine 28 (11), 2424-2435, 2022 | 69 | 2022 |
| Therapeutic vaccination refocuses T-cell responses towards conserved regions of HIV-1 in early treated individuals (BCN 01 study) B Mothe, C Manzardo, A Sanchez-Bernabeu, P Coll, S Morón-López, ... EClinicalMedicine 11, 65-80, 2019 | 64 | 2019 |
| Raltegravir intensification shows differing effects on CD8 and CD4 T cells in HIV-infected HAART-suppressed individuals with poor CD4 T-cell recovery M Massanella, E Negredo, J Puig, MC Puertas, MJ Buzón, ... Aids 26 (18), 2285-2293, 2012 | 62 | 2012 |
| Functional Consequences of Human Immunodeficiency Virus Escape from an HLA-B*13-Restricted CD8+ T-Cell Epitope in p1 Gag Protein JG Prado, I Honeyborne, I Brierley, MC Puertas, J Martinez-Picado, ... Journal of virology 83 (2), 1018-1025, 2009 | 62 | 2009 |
